Cigna Corporation is a global health service company that provides a comprehensive range of health insurance products and services. The company operates across various sectors, including medical, dental, disability, life, and accident insurance, offering coverage to individuals and families, as well as employer-sponsored group plans. Additionally, Cigna delivers integrated health services, such as pharmacy management, behavioral health support, and wellness programs, focusing on improving health outcomes and enhancing the overall well-being of its members. Through its innovative approaches, Cigna aims to create a seamless healthcare experience while addressing the diverse needs of its customers. Read More
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
SPONSORED CONTENT -- (StatePoint) Mental health issues, such as stress, anxiety and depression, are common among older adults, and can be exacerbated by declining health, loss of loved ones, financial challenges and late-in-life regrets.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Shares of health insurance company Cigna (NYSE:CI)
fell 3.1% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding the July 9th deadline for new US tariffs, now amplified by specific announcements.
UnitedHealth, Centene, and Elevance suffered steep market cap losses amid earnings guidance withdrawals and potential Medicaid changes tied to new legislation.
Shares of managed care provider Centene Corp. (NYSE: CNC) dropped over 40% on Wednesday, marking the worst single-day performance in the company's history.
As a landmark building in Beijing, CP Center has become the preferred office space for global enterprises entering the city, thanks to its unique international business appeal and exceptional operations and management.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Legal experts examine insurance pathways for psychedelic therapy as treatments near FDA review. Harvard research analyzes coverage models while BMU Law identifies three reimbursement pathways as insurers consider costs of MDMA and psilocybin treatments.
Cigna’s first-quarter results surpassed Wall Street’s revenue and non-GAAP profit expectations, with management highlighting strong performance from the company’s specialty pharmacy and pharmacy benefit services platforms. CEO David Cordani attributed momentum to the combined strengths of the EverNorth and Cigna Healthcare businesses, noting in particular the expansion of high-touch specialty services and broader adoption of biosimilar drugs. Cordani emphasized, “We delivered this performance in a dynamic environment with forces of change going beyond tariffs and trade, significant geopolitical, and evolving social impacts.” Management also pointed to disciplined capital deployment, including the completion of the Medicare business divestiture, as a contributor to the quarter’s results.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
